RxGen Advancing therapeutic development
 
 
about us
Management Team
Scientific Advisory Board
Board Of Directors
Consultants
Publications
News
Calendar

News

04.02.2008

RxGen Announces New Executive Promotions

03.27.2008

RxGen Supported Gene Silencing Study Reported in Nature

02.01.2008

RxGen Strives to Validate the African Green Monkey for Preclinical Research

09.01.07

RxGen Publishes African Green Monkey Data in Support of DART Reasearch

10.01.2006

RxGen Names D. James Coon to Director of Business Development of Preclinical Services

08.15.2005

RxGen Awarded Phase II of $1.6 Million Fast Track SBIR for PrimaToxTM, RxGen's Next Generation Toxicology Platform

12.07.2004

RxGen Awarded Phase I of Fast Track SBIR for Study of Environmental Causes of Parkinson's Disease

11.11.2004

RxGen Supports Development of Lipid Sciences' Delipidation Technology

10.05.2004

RxGen Awarded $1.4 Million Fast Track SBIR for Next Generation Predictive Toxicology Program, PrimaToxTM

09.15.2004

RxGen Appoints Steven R. Gullans, Former US Genomics CSO, as New Chief Executive Officer

08.20.2004

RxGen Discovers New Genes Associated with Brain Development
RxGen Brain Development Publication

About UsResearch and Consulting ServicesTechnologies & CapabilitiesPartnership OpportunitiesHome

Copyright © 2002-2006 RxGen

site by Acsys